Attention Journalists Covering ASN Kidney Week 2018,  

Several Mount Sinai nephrologists will be in attendance and available to comment on breaking news, in addition to their own research.   We will be making the following three physicians available:

Cijiang He, MD, Professor of Medicine and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai and the Irene and Dr. Arthur Fishberg endowed chair of Nephrology. Dr. He will be presenting on a new approach to treating diabetic kidney disease.

Dr. Girish Nadkarni is an Assistant Professor, Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai. Dr. Nadkarni will talk about hypertension.

Paolo Cravedi, MD, PhD, is an Assistant Professor in the Division of Nephrology in the Department of Medicine, Icahn School of Medicine at Mount Sinai. Dr. Cravedi will present his work on kidney transplantation in pediatric patients

Dr. Girish Nadkarni is an Assistant Professor, Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai. Dr. Nadkarni will talk about hypertension.

Please see below for more details about their presentations.

 

Please contact Tildy La Farge at tildy.lafarge@mountsinai to arrange an interview.

 

 

INVESTIGATORS DISCUSS NEW APPROACH IN TREATMENT OF DIABETIC KIDNEY DISEASE

OCTOBER 26

 

October 26, 4:30 – 6:30 PM

Abstract 3013673 "TYRO3 IS A NOVEL PODOCYTE PROTECTIVE FACTOR IN GLOMERULAR DISEASE"

Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I [OR0601-1]

Overview of Research

Diabetic kidney disease (DKD) is the common cause of end-stage renal disease. Therefore elucidating mechanisms that mediate kidney injury in the early stages of DKD may lead to novel preventive and therapeutic measures for DKD patients. Our recent research uncovered a novel renoprotective signaling mechanism by protein S in the early stages of DKD, which is mediated by the activation of its receptor TYRO3. Our results indicate that increased TYRO3 activity in kidney cells reduces diabetic injury and slows the kidney disease progression in the experimental model of diabetes.

 

Take home message:

Development of therapeutic measures to increase TYRO3 activity, such as a small molecule agonist of TYRO3, may be a new approach in treatment of DKD patients.

 

The principal investigator is Cijiang He, MD, Professor of Medicine and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai and the Irene and Dr. Arthur Fishberg endowed chair of Nephrology. 

Presentation Details

October 26, 4:30 – 6:30 PM

Abstract 3013673 "TYRO3 IS A NOVEL PODOCYTE PROTECTIVE FACTOR IN GLOMERULAR DISEASE"

Diabetic Kidney Disease: Mechanisms, Models, and Modulators - I [OR0601-1]

 

 

INVESTIGATORS USE INNOVATIVE STRATEGY TO UNDERSTAND IMMUNE SYSTEMS OF PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS  

 

Overview of research:

The development of antibodies against the donor represents a major risk factor for graft loss after kidney transplantation. The mechanisms that drive their formation are unclear and there is currently no effective treatment to remove these antibodies once they are formed.

The study used an innovative strategy (mass cytometry, CyTOF) to comprehensively characterize the immune system of pediatric kidney transplant recipients who developed donor-specific antibodies and found that immune changes occurs months before the detection of antibodies in the circulation, allowing for early treatments aimed at preventing their formation.

 

Take home message for media/general public:

We found early changes in the immune system of kidney transplant recipients that may be targeted to prevent formation of anti-donor antibodies, a major risk factor for graft loss.

 

The principal investigator is Paolo Cravedi, MD, PhD, Assistant Professor in the Division of Nephrology in the Department of Medicine, Icahn School of Medicine at Mount Sinai.

Presentation Details

10/27/2018 6:18 pm

Presenter:

Clara Fishman

(Paolo Cravedi’s lab)

CyTOF Analysis Identifies Antibody-Secreting and Memory B Cells >1 Year Prior to Antibody-Mediated Rejection (AMR) Development in Pediatric Kidney Transplant Recipients (SA-OR088)